ClinicalTrials.gg
CompletedNCT00564486Updated Oct 21, 2016Results posted

Analgesic Efficacy & Safety of Intravenous (IV) Acetaminophen Versus Placebo for the Treatment of Postop Pain

A Phase 3 interventional study of IV Placebo and IV Placebo in Pain, sponsored by Mallinckrodt. Completed at 17 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-21.

Sponsored by Mallinckrodt · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.

Enrollment
26th of 137
244 · median 95
Started
2007
with 7 others
Phase 3
22 of 137
none open now
Registered
19th of 137
by date
Lead sponsor
6 of 137
Mallinckrodt

Among the 137 studies testing acetaminophen in Pain, this one is the 26th largest by enrollment, is one of 8 that started in 2007, is one of 22 in phase 3, and was the 19th registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies testing acetaminophen in Pain, or all of them as a file.
02

Study summary

This research study will look at the pain relieving ability and safety of using repeated doses of intravenous (into the vein [IV]) acetaminophen in the treatment of moderate postoperative pain after planned or elective abdominal laparoscopic surgery, such as a laparoscopic abdominal hysterectomy or laparoscopic cholecystectomy (removal of the gall bladder).

Read the detailed description

To assess the analgesic efficacy of repeated doses of intravenous acetaminophen (IV APAP) versus Placebo in the treatment of moderate postoperative pain after abdominal laparoscopic surgery.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Abdominal Laparoscopic Surgery
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written prior to participation in the Study
  • Is scheduled to undergo abdominal laparoscopic surgery under general anesthesia (laparoscopic bariatric procedures, including gastric bypass or gastric banding, laparoscopic exploratory procedures in which no visceral dissection is performed, and laparoscopic procedures with minimal visceral dissection, such as laparoscopic sterilization,are excluded)
  • If Subject is a female of , have a negative pregnancy test within 21 days of surgery
  • Be at least 18, but not more than 80 years of age
  • Have a (BMI) ≥ 19 and ≤ 40 lb/in2
  • Have an (ASA) risk class of I, II, or III
  • Have the ability to read and understand the Study procedures and the use of the pain scales and have the ability to communicate meaningfully with the Study Investigator and staff
  • Be free of other physical, mental, or medical conditions which, in the opinion of the Investigator, makes Study participation inadvisable

Exclusion criteria

Exclusion Criteria:

  • Used opioids or tramadol daily for greater than 7 days prior to Study Medication administration (Subjects who, in the Investigator's opinion have or are developing opioid tolerance are to be excluded)
  • Has been treated with Chapparal, Comfrey, Germander, Gin Bu Huan, Kava, Pennyroyal, Skullcap, St. John's Wort, or Valerian within 14 days prior to surgery
  • Has significant medical disease(s), laboratory abnormalities or condition(s) that in the Investigator's judgment could compromise the Subject's welfare, ability to communicate with the Study staff, complete Study activities, or would otherwise contraindicate Study participation
  • Has known to opioids, acetaminophen, or the inactive ingredients () of the Study Medication
  • Has known or suspected history of alcohol or drug abuse or dependence within the previous 2 years
  • Has impaired liver function, e.g., (AST)/Alanine transaminase (ALT)/ greater than or equal to 3.0 times the , active hepatic disease, evidence of liver disease, or other condition (e.g., alcoholism, cirrhosis, or hepatitis) that may suggest the potential for an increased susceptibility to hepatic toxicity with Study Medication exposure
  • Has been treated with monoamine oxidase inhibitors (MAOIs) within 7 days prior to surgery
  • Has participated in another clinical Study ( or marketed product) within 30 days of surgery

Post Operative Exclusion Criteria

The Subject must not meet any of the following criteria prior to randomization to Study Medication:

  • Had any other surgery than the planned laparoscopic surgery or had intra operative or post operative complications which in the view of the Investigator would make Study participation inadvisable
  • Has taken non steroidal anti-inflammatory drugs (NSAIDs), or MAOIs during the day after surgery. Exceptions: The use of low-dose aspirin, e.g, 81 mg/day, for cardioprophylaxis, and limited use of topical or inhaled steroids are acceptable.
  • Had any neuraxial (spinal or epidural) opioid injected perioperatively
  • Had a local anesthetic injection (including into surgical wound at closure) or continuous infusion by any route
  • Had an epidural, regional, or percutaneous (intrawound) catheter with continuous local anesthetic infusion used for postoperative analgesic management
  • Had a fever (greater than 38.6 ºC or 101.5 ºF) requiring treatment

Post Operative Day 1 Randomization Criterion On the morning of the first post operative day (POD1), the Subject must have a categorical pain intensity score at rest of moderate or severe and a score ≥ 40 mm and ≤ 70 mm at rest on a 100 mm Visual Analogue Scale (VAS)

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
244 participants (actual)

Study arms

  • Placebo comparator
    IV Placebo 100 ml

    IV Placebo 100 ml dosed every every 6 hours for 24 hours (4 doses total).

    Drug: IV Placebo

  • Placebo comparator
    IV Placebo 65 ml

    IV Placebo 65 ml dosed every every 4 hours for 24 hours (6 doses total).

    Drug: IV Placebo

  • Experimental
    IV Acetaminophen 1 gm

    IV Acetaminophen 1 gm dosed every every 6 hours for 24 hours (4 doses total).

    Drug: IV Acetaminophen

  • Experimental
    IV Acetaminophen 650 mg

    IV Acetaminophen 650 mg dosed every every 4 hours for 24 hours (6 doses total).

    Drug: IV Acetaminophen

Interventions

  • DrugIV Placebo

    IV, every 6 hours for 24 hours (4 doses total)

    Also known as: placebo

  • DrugIV Placebo

    IV, every 4 hours for 24 hours (6 doses total)

    Also known as: placebo

  • IV, every 6 hours for 24 hours (4 doses total)

    Also known as: APAP, IV APAP

  • IV, every 4 hours for 24 hours (6 doses total)

    Also known as: APAP, IV APAP

06

What researchers measure

Primary outcomes

  1. Sum Pain Intensity Difference - Baseline to 24 Hours (SPID24), 1 g IV Acetaminophen vs. Placebo (PI Was Measured at the Timepoints of T0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, and 24 Hours.)

    Pain Intensity (PI) as measured by a 100 millimeter (mm) long Visual Analogue Scale (VAS) over 24 hours after treatment minus the Baseline VAS score. The 100 mm VAS was drawn on a pain ruler and labeled at its left end with '0 = No Pain' and with "100 = Worst Pain Imaginable' at its right end. Subjects placed a mark on the scale to represent their perceived pain. The score was the distance in mm from the left end of the VAS to the point where the subject's mark crossed the line. PI at baseline was compared to the PI at each timepoint and differences were summed over the 24 hour time period.

    Time frame: Baseline to 24 hrs

Secondary outcomes

  1. Sum Pain Intensity Difference - Baseline to 24 Hours (SPID24), 650 mg IV Acetaminophen vs. Placebo (PI Was Measured at the Timepoints of T0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, and 24 Hours.)

    Sum of Pain Intensity (PI) as measured by the 100 mm long Visual Analogue Scale (VAS) over 24 hours after treatment subtracting the Baseline VAS score.The 100 mm VAS was drawn on a pain ruler and labeled at it's left end with "0 = No Pain' and its right end with '100 = Worst Pain Imaginable.' Subjects placed a mark on the scale to represent their perceived pain. The score was the distance in mm from the left end of the VAS to the point where the subject's mark crossed the line. PI difference from baseline was calculated at each assessment over a 24 hour period.

    Time frame: Baseline to 24 hrs

  2. The Number of Subjects Reporting a Treatment Emergent Adverse Event

    Number of subjects who experienced at least one treatment emergent adverse event (TEAE). A TEAE is an adverse event that occurs on or after the first dose of study medication (T0).

    Time frame: First dose through 7 day follow up

  3. The Number of Subjects Reporting a Treatment Emergent Serious Adverse Event

    The number of subjects who reported at least one treatment emergent SAE during the study. A Serious Adverse Event is defined as any untoward medical occurrence at any dose of blinded study medication that: * results in death * is life-threatening * requires inpatient hospitalization or causes prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event

    Time frame: First dose to 30 days after last dose of study medication.

07

Results

Posted Nov 30, 2010
Limitations and caveats
One subject was randomized to receive IV APAP 1 g, but was administered IV APAP 650 mg. The subject was included in 1g IV APAP group for efficacy purposes and included in IV APAP 650 mg safety group for AE purposes.

Participant flow

The study was conducted at 17 sites across the US from 27 Nov 2007 to 12 September 2008.

Participant flow — Overall Study
MilestoneIntravenous (IV) Placebo (100 ml)IV Acetaminophen 1 gmIV Acetaminophen 650 mgIV Placebo (65 ml)
Started43924267
Completed36913960
Not completed7137
Withdrew: Adverse event0100
Withdrew: Withdrawal by subject4005
Withdrew: Subject refused to have blood drawn0010
Withdrew: Lost to follow-up3022

Outcome measures

PrimarySum Pain Intensity Difference - Baseline to 24 Hours (SPID24), 1 g IV Acetaminophen vs. Placebo (PI Was Measured at the Timepoints of T0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, and 24 Hours.)

Pain Intensity (PI) as measured by a 100 millimeter (mm) long Visual Analogue Scale (VAS) over 24 hours after treatment minus the Baseline VAS score. The 100 mm VAS was drawn on a pain ruler and labeled at its left end with '0 = No Pain' and with "100 = Worst Pain Imaginable' at its right end. Subjects placed a mark on the scale to represent their perceived pain. The score was the distance in mm from the left end of the VAS to the point where the subject's mark crossed the line. PI at baseline was compared to the PI at each timepoint and differences were summed over the 24 hour time period.

Time frame:
Baseline to 24 hrs
Reported as:
Mean · Units on a scale
Sum Pain Intensity Difference - Baseline to 24 Hours (SPID24), 1 g IV Acetaminophen vs. Placebo (PI Was Measured at the Timepoints of T0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, and 24 Hours.)
Units on a scaleIV PlaceboIV Acetaminophen 1 gm
Sum Pain Intensity Difference - Baseline to 24 Hours (SPID24), 1 g IV Acetaminophen vs. Placebo (PI Was Measured at the Timepoints of T0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, and 24 Hours.)-45.2 ± 513.25-194.1 ± 593.62
SecondarySum Pain Intensity Difference - Baseline to 24 Hours (SPID24), 650 mg IV Acetaminophen vs. Placebo (PI Was Measured at the Timepoints of T0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, and 24 Hours.)

Sum of Pain Intensity (PI) as measured by the 100 mm long Visual Analogue Scale (VAS) over 24 hours after treatment subtracting the Baseline VAS score.The 100 mm VAS was drawn on a pain ruler and labeled at it's left end with "0 = No Pain' and its right end with '100 = Worst Pain Imaginable.' Subjects placed a mark on the scale to represent their perceived pain. The score was the distance in mm from the left end of the VAS to the point where the subject's mark crossed the line. PI difference from baseline was calculated at each assessment over a 24 hour period.

Time frame:
Baseline to 24 hrs
Reported as:
Mean · Units on a scale
Sum Pain Intensity Difference - Baseline to 24 Hours (SPID24), 650 mg IV Acetaminophen vs. Placebo (PI Was Measured at the Timepoints of T0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, and 24 Hours.)
Units on a scaleIV PlaceboIV Acetaminophen 650 mg
Sum Pain Intensity Difference - Baseline to 24 Hours (SPID24), 650 mg IV Acetaminophen vs. Placebo (PI Was Measured at the Timepoints of T0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, and 24 Hours.)-45.2 ± 513.25-323.1 ± 619.27
SecondaryThe Number of Subjects Reporting a Treatment Emergent Adverse Event

Number of subjects who experienced at least one treatment emergent adverse event (TEAE). A TEAE is an adverse event that occurs on or after the first dose of study medication (T0).

Time frame:
First dose through 7 day follow up
Reported as:
Number · Subjects
The Number of Subjects Reporting a Treatment Emergent Adverse Event
SubjectsIV PlaceboIV Acetaminophen 1000 mgIV Acetaminophen 650 mg
The Number of Subjects Reporting a Treatment Emergent Adverse Event686528
SecondaryThe Number of Subjects Reporting a Treatment Emergent Serious Adverse Event

The number of subjects who reported at least one treatment emergent SAE during the study. A Serious Adverse Event is defined as any untoward medical occurrence at any dose of blinded study medication that: * results in death * is life-threatening * requires inpatient hospitalization or causes prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * is an important medical event

Time frame:
First dose to 30 days after last dose of study medication.
Reported as:
Number · Subjects
The Number of Subjects Reporting a Treatment Emergent Serious Adverse Event
SubjectsIV PlaceboIV Acetaminophen 1 gmIV Acetaminophen 650 mg
The Number of Subjects Reporting a Treatment Emergent Serious Adverse Event213

Adverse events

Collected over Adverse Events were collected from T0 (on or after start of study drug) to Day 7 after surgery. Serious Adverse Events were collected from T0 to 30 days after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravenous (IV) Placebo (100 ml)—0/43 (0%)12/43 (27.9%)
IV Acetaminophen 1 gm—1/91 (1.1%)42/91 (46.2%)
IV Acetaminophen 650 mg—3/43 (7%)16/43 (37.2%)
IV Placebo (65 ml)—2/67 (3%)27/67 (40.3%)
Most frequent serious events
Most frequent serious events
EventIntravenous (IV) Placebo (100 ml)IV Acetaminophen 1 gmIV Acetaminophen 650 mgIV Placebo (65 ml)
Postoperative ileusInjury, poisoning and procedural complications0/430/912/430/67
Impaired gastric emptyingGastrointestinal disorders0/430/911/430/67
Small intestinal obstructionGastrointestinal disorders0/430/911/430/67
Postoperative abscessInfections and infestations0/430/910/431/67
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/430/910/431/67
VomitingGastrointestinal disorders0/431/910/430/67
Most frequent other events
Showing 10 of 12
Most frequent other events
EventIntravenous (IV) Placebo (100 ml)IV Acetaminophen 1 gmIV Acetaminophen 650 mgIV Placebo (65 ml)
ConstipationGastrointestinal disorders7/4316/915/4311/67
NauseaGastrointestinal disorders3/4316/914/439/67
FlatulenceGastrointestinal disorders4/4314/914/436/67
HeadacheNervous system disorders4/4312/914/438/67
PyrexiaGeneral disorders5/432/910/432/67
VomitingGastrointestinal disorders0/437/914/432/67
Back painMusculoskeletal and connective tissue disorders1/431/912/436/67
DiarrhoeaGastrointestinal disorders1/433/910/435/67
InsomniaPsychiatric disorders1/432/913/434/67
DypsnoeaRespiratory, thoracic and mediastinal disorders0/430/913/430/67

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IV PlaceboIV Acetaminophen 1 gmIV Acetaminophen 650 mgTotal
<=18 years0000
Between 18 and 65 years1008638224
>=65 years106420
Sex: Female, Male
Sex: Female, Male(Participants)IV PlaceboIV Acetaminophen 1 gmIV Acetaminophen 650 mgTotal
Female917433198
Male1918946
08

Study locations

17 sites
  • Helen Keller Hospital
    Sheffield, Alabama 35660, United States
  • Precision Trials
    Phoenix, Arizona 85032, United States
  • Methodist Hospital
    Arcadia, California 91007, United States
  • Glendale Adventist Medical Center
    Glendale, California 91206, United States
  • Physicians Clinical Research Corporation
    Laguna Hills, California 92653, United States
  • Huntington Memorial Hospital
    Pasadena, California 91105, United States
  • Visions Clinical Research
    Boynton Beach, Florida 33414, United States
  • Nature Coast Clinical Research
    Crystal River, Florida 34429, United States
  • G and G Research, Inc.
    Fort Pierce, Florida 34950, United States
  • Advanced Surgery Associates at Mercy Hospital
    Miami, Florida 33133, United States
  • University of Miami School of Medicine
    Miami, Florida 33136, United States
  • William Beaumont Hospital (Royal Oak)
    Royal Oak, Michigan 48073, United States
  • William Beaumont Hospital (Troy)
    Royal Oak, Michigan 48073, United States
  • Cooper University Hospital
    Camden, New Jersey 08103, United States
  • Staten Island University Hospital
    Staten Island, New York 10305, United States
  • Memorial Herman/Memorial City Hospital
    Houston, Texas 77024, United States
  • Texas Woman's Hospital
    Houston, Texas 77024, United States
09

References and documents

Publications

  • Wininger SJ, Miller H, Minkowitz HS, Royal MA, Ang RY, Breitmeyer JB, Singla NK. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery. Clin Ther. 2010 Dec;32(14):2348-69. doi: 10.1016/j.clinthera.2010.12.011. PubMed 21353105 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 2 years 2 months after primary completion. A results delay was requested in Apr 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2007
First posted
Nov 28, 2007
Start
Nov 2007
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results delay requested
Apr 3, 2009
Results first posted
Nov 30, 2010
Last update
Oct 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00564486
Lead sponsor
Mallinckrodt
Responsible party
Sponsor
First posted
Nov 28, 2007
Start date
Nov 2007
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Nov 30, 2010
Last update
Oct 21, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion